164 related articles for article (PubMed ID: 38615173)
1. Clinical applications of abnormal DNA methylation in chronic myeloid leukemia.
Zhou L; Yin X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Jan; 49(1):122-127. PubMed ID: 38615173
[TBL] [Abstract][Full Text] [Related]
2. Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response.
Behzad MM; Shahrabi S; Jaseb K; Bertacchini J; Ketabchi N; Saki N
Biochem Genet; 2018 Jun; 56(3):149-175. PubMed ID: 29388070
[TBL] [Abstract][Full Text] [Related]
3. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
[TBL] [Abstract][Full Text] [Related]
4. Methylation status of DDIT3 gene in chronic myeloid leukemia.
Wang YL; Qian J; Lin J; Yao DM; Qian Z; Zhu ZH; Li JY
J Exp Clin Cancer Res; 2010 May; 29(1):54. PubMed ID: 20492726
[TBL] [Abstract][Full Text] [Related]
5. SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia.
Wu DL; Wang Y; Zhang TJ; Chu MQ; Xu ZJ; Yuan Q; Ma JC; Lin J; Qian J; Zhou JD
Eur J Med Res; 2022 Nov; 27(1):259. PubMed ID: 36411451
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34
Maupetit-Mehouas S; Court F; Bourgne C; Guerci-Bresler A; Cony-Makhoul P; Johnson H; Etienne G; Rousselot P; Guyotat D; Janel A; Hermet E; Saugues S; Berger J; Arnaud P; Berger MG
Mol Oncol; 2018 Jun; 12(6):814-829. PubMed ID: 29575763
[TBL] [Abstract][Full Text] [Related]
7. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
8. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
[TBL] [Abstract][Full Text] [Related]
9. [New insight into DNA methylation in CML and its effect on clinical outcome--review].
Tang Y; Hu JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1482-6. PubMed ID: 19099669
[TBL] [Abstract][Full Text] [Related]
10. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
[TBL] [Abstract][Full Text] [Related]
11. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
Zion M; Ben-Yehuda D; Avraham A; Cohen O; Wetzler M; Melloul D; Ben-Neriah Y
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10722-6. PubMed ID: 7938018
[TBL] [Abstract][Full Text] [Related]
12. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
Jelinek J; Gharibyan V; Estecio MR; Kondo K; He R; Chung W; Lu Y; Zhang N; Liang S; Kantarjian HM; Cortes JE; Issa JP
PLoS One; 2011; 6(7):e22110. PubMed ID: 21760961
[TBL] [Abstract][Full Text] [Related]
13. Methylation status of CEBPA gene promoter in chronic myeloid leukemia.
Annamaneni S; Kagita S; Gorre M; Digumarti RR; Satti V; Battini MR
Hematology; 2014 Jan; 19(1):42-4. PubMed ID: 23541085
[TBL] [Abstract][Full Text] [Related]
14. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
Vatanmakanian M; Tavallaie M; Ghadami S
Cell Commun Signal; 2019 Apr; 17(1):38. PubMed ID: 31014357
[TBL] [Abstract][Full Text] [Related]
15. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia.
Qian J; Wang YL; Lin J; Yao DM; Xu WR; Wu CY
Eur J Haematol; 2009 Feb; 82(2):119-23. PubMed ID: 19018866
[TBL] [Abstract][Full Text] [Related]
16. [The methylation of CT gene in chronic myeloid leukemia].
Zhou J; Xue Y; Lin B
Zhonghua Nei Ke Za Zhi; 1997 Jun; 36(6):394-7. PubMed ID: 10374299
[TBL] [Abstract][Full Text] [Related]
17. p53 mutations, methylation and genomic instability in the progression of chronic myeloid leukaemia.
Guinn BA; Mills KI
Leuk Lymphoma; 1997 Jul; 26(3-4):211-26. PubMed ID: 9322884
[TBL] [Abstract][Full Text] [Related]
18. Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia.
Uhm KO; Lee ES; Lee YM; Park JS; Kim SJ; Kim BS; Kim HS; Park SH
J Korean Med Sci; 2009 Jun; 24(3):493-7. PubMed ID: 19543515
[TBL] [Abstract][Full Text] [Related]
19. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
20. [Methylation status of id4 gene promoter in patients with chronic myeloid leukemia].
Wang XR; Kang HY; Cen J; Li YH; Wang LL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1402-4. PubMed ID: 21176338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]